BC Innovations | Mar 10, 2016
Distillery Therapeutics

Therapeutics: Thymic stromal lymphopoietin (TSLP)

Cancer INDICATION: Breast cancer; pancreatic cancer Mouse studies suggest promoting dermal expression of TSLP could help treat breast cancer. In a mouse model of breast cancer, transgenic expression of human TSLP in the skin decreased...
BC Innovations | Oct 9, 2014
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Pancreatic cancer Vitamin D receptor (VDR) In vitro and mouse studies suggest vitamin D analogs could help treat pancreatic cancer. VDR levels were higher in...
BC Week In Review | Sep 2, 2013
Clinical News

Akvano/calcipotriol: Phase I/IIa data

A double-blind Phase I/IIa trial in 24 patients with psoriasis vulgaris showed that 10 topical applications of Akvano/calcipotriol over 12 days met the primary endpoint of reducing psoriatic infiltrate thickness as measured by sonography vs....
BC Innovations | May 16, 2013
Distillery Therapeutics

Indication: Hepatic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Hepatic disease Liver fibrosis Mothers against decapentaplegic homolog 3 (MADH3; SMAD3); transforming growth factor receptor-b1 (TGFB1); vitamin D receptor (VDR) In vitro...
BC Week In Review | Mar 15, 2010
Clinical News

Valrubicin cream: Phase IIa started

Valderm began a double-blind, placebo-controlled, international Phase IIa trial to compare 2 strengths of valrubicin cream applied once daily under occlusion vs. calcipotriol and betamethasone valerate. The study will also compare valrubicin cream applied once...
BC Innovations | Jan 7, 2010
Targets & Mechanisms

HCV cache: the list

Researchers at The Scripps Research Institute have used a cell-based model of HCV infection to identify compounds on the market or in development for other indications that could be repurposed to treat HCV. 1 But...
BC Week In Review | Nov 3, 2008
Clinical News

DPS-101: Phase IIb data

A double-blind, European Phase IIb trial in 168 patients showed that the highest dose of DPS-101 met all the primary and secondary endpoints. Patients received 0.05%, 0.1%, 0.7% or 1.4% nicotinamide plus 0.005% calcipotriol twice...
BC Week In Review | Oct 27, 2008
Clinical News

DPS-102: Phase II start

In December, Dermipsor will begin a double-blind, U.S. Phase II trial (2008-103) to compare topical DPS-102 vs. placebo, calcipotriol monotherapy, or nicotinamide monotherapy in 160 patients. The company is developing the product under a CRADA...
BC Week In Review | Sep 22, 2008
Clinical News

INCB18424: Phase IIa data

A double-blind, dose-escalating Phase IIa trial (Study 201) in 28 patients showed that 1.0% once-daily and 1.5% twice-daily topical INCB18424 significantly decreased mean total lesion scores by 53% and 54%, respectively, compared with 32% and...
BC Week In Review | Feb 6, 2006
Clinical News

Carbenoxolone: Preliminary Phase II data

Preliminary data from a Phase II trial in 12 patients with mild to moderate psoriasis showed clinical activity as measured by >=50% reduction in redness, scaling and thickness of plaques. Patients received 2% carbenoxolone gel,...
Items per page:
1 - 10 of 12